Rationale: Vascular calcification (VC) is a marker of the severity of atherosclerotic disease. Hormones play important roles in regulating calcification; estrogen and parathyroid hormones exert opposing effects, the former alleviating VC and the latter exacerbating it. To date no treatment strategies have been developed to regulate clinical VC.
V ascular calcification (VC) is a hallmark of atherosclerosis and a key prognostic indicator of chronic kidney disease. In addition to chronic kidney disease and atherosclerosis, risk factors include advanced age and diabetes mellitus. The consequences of VC may include exacerbated aortic valvular failure, arterial stiffness, acute myocardial infarction, and stroke related to rupture of atherosclerotic plaque. Whereas global or macrocalcification correlates more closely with stabilized plaque and is considered protective, there is evidence that lesions at earlier stages of VC identified histologically as diffuse, speckled, or microcalcified are associated with unstable plaques and may promote plaque rupture by exacerbating shear stress. [1] [2] [3] [4] [5] 
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The development of VC involves passive chemical reactions that deposit hydroxyapatite on the vessel walls and active cellular processes regulated by extracellular apoptotic vesicles within the plaque, and thus the osteogenesis of resident cells, especially of smooth muscle cells (SMCs) that are stimulated by activation of proinflammatory nuclear factor-κB (NFκB) signaling. [6] [7] [8] To date, no effective agents are available to regulate arterial calcification linked with atherosclerosis although clinical trials of sevelamer, a phosphate-binding drug, were shown to slow coronary artery calcification and reduce mortality of patients with chronic kidney disease. 9, 10 Hormones can regulate VC by activating G-proteincoupled receptors. Estrogen was shown to alleviate VC in human SMCs by inhibiting ligand of receptor activator for nuclear factor-κ B (RANKL) signaling. 11 Cortistatin attenuated VC in a rat calcification model by decreasing expression of a sodium-dependent phosphate cotransporter-1 (Pit-1) and lowering alkaline phosphatase (ALP) activity in SMCs. 12 Similar effects were described for ghrelin, a neuropeptide hormone that regulates appetite with opposite effects to leptin. 12 In contrast, parathyroid hormones exacerbate calcification by increasing the circulating levels of available calcium and phosphate. [13] [14] [15] Although some hormone therapies have proven to be effective in ameliorating VC in animal models, their clinical application is limited by serious adverse side effects that accompany the requirement for chronic administration.
Growth hormone-releasing hormone (GHRH) is a neuropeptide produced by the hypothalamic arcuate nucleus neurons; it binds to class-2 G-protein-coupled receptors (GHRH-R) in the pituitary where it stimulates the release of growth hormone (GH) in a cAMP-dependent manner. 16 Besides its expression on the pituitary cells, GHRH and its receptors are also detected on other cells, including fibroblasts, 17 cardiomyocytes, 18 and mesenchymal stem cells. 19 GHRH-Rs decrease with age in most but not all the tissues studied. [20] [21] [22] Synthetic agonists of GHRH (GHRH-A), with increased stability compared with the native GHRH peptide, 16, 23 have been used to treat experimental diabetes mellitus, 24 myocardial infarction, 18, 25 and lung damage 26 in animal models. We have previously demonstrated that mesenchymal stem cells pretreated with GHRH-A markedly improved therapeutic angiogenesis of ischemic hindlimb by enhancing the viability and mobility of mesenchymal stem cells. 19 The mechanisms and signaling pathways of atherosclerotic plaque calcification driven by inflammation are well described. 27, 28 The signals converge on the regulation of osteogenic differentiation of precursor cells resident in the tunica media, plaque intima, or cap, usually SMCs or pericytes. 8, 29 The pathogenesis of VC shares many similar biological processes with bone morphogenesis, which involves the same intermediates, including the canonical bone morphogenic family proteins that respond to inflammatory stimuli and activate the RANK pathway upstream of NFκB, Runx2, and ALP. The roles of reactive oxygen species (ROS) in promoting osteogenesis are also well described. 30, 31 Excess ROS accelerate atherogenesis 32 and arterial calcification 30 and may directly activate the calcification of SMC through NFκB and Runx2. CAMP and protein kinase A (PKA) can downregulate ROS by inhibiting the activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidases 33 and also exert direct regulation of downstream NFκB signaling. [33] [34] [35] The osteogenic pathway is blocked by osteoprotegerin, a decoy receptor of RANKL, 36 
Novelty and Significance
What Is Known?
• Growth hormone-releasing hormone (GHRH) is a neuropeptide produced by the hypothalamic arcuate nucleus neurons; it binds to class-2 G-protein-coupled receptors in the pituitary where it stimulates the release of growth hormone in a cAMP-dependent manner • The transdifferentiation of smooth muscle cells to osteoblast-like cells plays a key role in vascular calcification.
• Several signaling pathways are involved in ectopic calcification, including cAMP/protein kinase A, and ligand of receptor activator for nuclear factor-κ B/nuclear factor-κB (p65).
What New Information Does This Article Contribute?
• Agonists of GHRH alleviates smooth muscle cell-mediated aortic calcification in osteoprotegerin knockout mice.
• Reduction of aorta calcification by agonists of GHRH is associated with activation of cAMP/protein kinase A and the deactivation of receptor activator for nuclear factor-κ B/nuclear factor κB(p65) signaling pathways.
• Activation of protein kinase A leads to dephosphorylation of nuclear factor κB (p65) and thence reduction of inflammation-associated vascular calcification.
Prevention of aortic calcification by agonists of GHRH is mediated by cross talk between cAMP/protein kinase A and receptor activator for nuclear factor-κ B/nuclear factor κB signaling pathways. These findings may provide a new target and safe strategy to treat aorta calcification and other related indications that involve vascular calcification.
glycoprotein synthesized in the liver, paricalcitol a Wnt/β-catenin inhibitor, and pyrophosphate. 29, 37, 38 Previous work has also demonstrated that GHRH-A can stimulate several other major signaling pathways, including cAMP/PKA, AKT (protein kinase B), and ERK (extracellular regulated protein kinase), without affecting expression of GH/IGF (insulin-like growth factor)-1/2. 18, 39, 40 In the present study, we tested the hypothesis that the activation of GHRH-R by MR409, a selective GHRH agonist, suppresses SMC calcification by driving cAMP/PKA signaling and blocking NFκB and ROS signaling pathways.
Methods
The authors declare that all data that support the findings of this study are available within the article and its Online Data Supplement files.
Full description of Materials and Methods is available in the Online Data Supplement. Vascular SMCs were isolated from aortas of 8-week-old wild-type C57BL/6 or osteoprotegerin-deficient (OPG −/− ) mice and aortas of heart transplant patients. OPG −/− mice were used to model arterial calcification. Results are presented as means±SD.
Results

GHRH and GHRH-A (MR409) Inhibit Calcification of Human SMCs
Previous work has shown that GH, GHRH, or GHRH-A can activate PKA, Akt, and ERK signaling pathways 24, 41 and reduce ROS production. 42 Therefore, we assumed that GHRH and GHRH-A would block osteogenesis by interfering with RANK-NFκB-Runx2 signaling through cAMP-dependent PKA. In preliminary work to test this concept, we exposed human aortic SMCs to osteogenic medium (OM) for 2 to 3 weeks in the presence and absence of recombinant human GHRH or GHRH-A (MR409) and measured calcification. As shown in Figure 1 , both recombinant human GHRH and MR409 significantly reduced calcification as shown by Alizarin Red staining (P<0.01; n=3; Figure 1A and 1B; Online Figure IA and IB). Total calcium was decreased by 45% and 50%, respectively, by recombinant human GHRH or MR409 compared with untreated controls (P<0.01; n=3; Figure 1C ). In both cases, the anticalcification effects were blocked by addition of antagonist MIA602, a competitive inhibitor of MR409, confirming the specificity of MR409 actions. It should be noted that the low dose of MR409 used in our studies does not induce chronic elevation of serum GH in vivo despite its potent and sustained activation of GHRH signaling. 40 Consistent with this, and in contrast to recombinant human GHRH treatment, low-dose MR409 does not promote acromegaly that results from sustained high serum levels of GH. 43, 44 Consequently, our mechanistic studies of VC in this model were confined to MR409.
MR409 Attenuates Vascular Calcification in OPG −/− Mice
To determine whether MR409 also blocks calcification in vivo, OPG −/− mice were treated for 4 weeks with daily subcutaneous injections of MR409 as described in the Methods. Microcomputed tomographic scans ( Figure 2A ) showed no calcification on aortas of wild-type C57BL/6 mice, but calcification was evident in both treated (11 of 18) and nontreated (12 of 17) OPG −/− groups (Online Figure II) . Quantification of calcification revealed significantly less calcium deposition on 
MR409 Inhibits Calcification in Mouse AortaDerived SMCs
GHRH receptors were detected on the membranes of SMCs derived from human and mouse aortas by both confocal microscopy and Western blot (Online Figure IV) . When cultured in OM, SMCs developed profound calcium deposition as visualized by Alizarin Red and Von Kossa staining ( Figure 3A ). MR409 treatment significantly reduced the calcification of SMCs under OM (P<0.01; n=3) in a dose-dependent manner (Online Figure V) . MR409 did not influence proliferation or migration of SMCs under OM conditions (Online Figure VI) . The effect of MR409 was partially blocked by GHRH antagonist, MIA602. Moreover, small interfering RNA (siRNA)-mediated knock-down of GHRH-R abolished the protective effects of MR409 ( Figure 3A and 3B) , further confirming the selectivity of MR409 for the GHRH signaling pathway. Significantly, less calcium was deposited on SMCs cultured with MR409 as compared with controls, and the effects of MR409 were reversed by treatments with MIA602 or siR-NA against the GHRH receptor (P<0.001; n=3; Figure 3C ). MR409 treatment reduced ALP activity (P<0.001; n=3; Figure 3D ) and protein expression levels of Runx2, osteonectin, and osteocalcin in SMCs (Figure 3E and 3F; P<0.01; n=3) but not osteopontin. The absorption of radioactive isotope 32P into the cytoplasm of SMCs was not influenced by MR409 (data not shown). Taken together, these data confirm the suppression of SMC calcification in vitro by MR409.
MR409 Reduces ROS Production by Inhibiting the Activity of NADPH Oxidases
ROS are known to induce osteogenic differentiation, and GHRH-A have been shown to reduce radiation-induced ROS. 42 Therefore, we measured ROS production and related gene expression in SMCs under different conditions. ROS were significantly increased when SMCs were cultured in OM, and this effect was blocked by treatment with MR409. The inhibition of ROS by MR409 was reversed by treatments with the antagonist MIA602 or by siRNA against GHRH-R (P<0.001; Figure 4A and 4B). To further explore the mechanism of GHRH-A-mediated inhibition of SMC calcification, we applied gene expression arrays to SMCs cultured with or without MR409 (Online Figure VII) . Gene ontology-analyses implicated the downregulation of superoxide-generating pathways by treatment with MR409. NADPH oxidase genes expression, determined by reverse transcription polymerase chain reaction, was reduced by up to 40% (Online Figure  VIII) . The increased NADPH oxidase activity under OM condition was also effectively blocked by MR409 (P<0.001; Figure 4C ). Similar results were observed in human and opg −/− mouse SMCs (Online Figure IX) . These results implicate inhibition of NADPH oxidases as an intermediate in the decreased production of ROS by treatment of osteogenic SMCs with MR409.
Inhibition of NADPH Oxidase Activity by MR409 Is Mediated by cAMP/PKA Signaling
GHRH-A stimulates the G-protein-coupled GHRH receptor and increases cAMP/PKA activity in multiple cell types. 41 Consistent with this, we also found that cytoplasmic cAMP levels in SMCs were increased by MR409 treatment, and the effect was partially abolished by antagonist MIA602 ( Figure 5A ; Online Figure Ⅹ) . Inhibition of PKA by a specific siRNA or by the chemical inhibitor H89 blocked the suppressive effect of MR409 on NADPH oxidases ( Figure 5B ) and ROS production ( Figure 5C ), confirming that PKA is a downstream intermediate of MR409. As expected, the anticalcification effects of MR409 were also abolished by inhibition of PKA ( Figure 5D and 5E). Similar results were obtained with human SMCs (Figure 5F and 5G). These data indicate that MR409 inhibits NADPH oxidase and ROS generation by activating the cAMP/PKA signaling pathway in both mouse and human SMCs.
MR409 Blocks Phosphorylation of NFκB Through PKA In Vitro
The NFκB pathway is a central regulator of osteogenesis, and previous studies have shown cross talk between PKA and NFκB. 35, 46 We found that phosphorylation of NFκB (p65) was significantly increased under OM conditions, and this was blocked by MR409 ( Figure 6A and 6B) . The effect of MR409 was reversed by a PKA-specific siRNA ( Figure 6A and 6B) . Consistent with this, the expressions of Runx2 and IL-6 (interleukin-6), target genes of NFκB (p65), responded in parallel with the phosphorylation of NFκB (p65; Figure 6A , 6C, and 6D). SMCs exposed to OM exhibited high expression of RANKL that was unaffected by cotreatment with MR409 ( Figure 6E ). We found that the markedly increased phosphorylation of NFκB (p65) and IL-6 expression in SMCs isolated from OPG −/− mice ( Figure 6F ) was reversed by MR409 treatment, and this effect was blocked by treating cells with a PKA-specific siRNA, PKA inhibitor H89, or GHRH antagonist MIA602 and a GHRH-R-specific siRNA ( Figure 6F and 6G). These results suggest that MR409 acts through activation of PKA to block phosphorylation of NFκB (p65) and propagation of the osteogenic signal.
MR409 Promotes Dephosphorylation of Aortic NFκB Without Changing Normal Physiological Parameters of Other Tissues and Organs
Osteoprotegerin deficiency in OPG −/− mice results in elevated serum RANKL with activation of the RANK pathway and its target NFκB. Constitutive activation of NFκB promotes excess calcification of target cells, a distinguishing phenotype of OPG −/− mice. 45 Consistent with this, we observed higher RANKL concentrations in the circulation of OPG −/− mice that were unaffected by treatment of mice with MR409 ( Figure 7A ). Consistent with the results shown in Figure 6E , MR409 does not seem to act at the level of RANKL. Rather, we found that IL-6 expression in aortas of OPG −/− mice increased in parallel with p65 phosphorylation, and this increase was abrogated by treatment of OPG −/− mice with MR409 ( Figure 7B and 7C ). The decreased phospho-p65 was observed in both cytoplasm and nuclei ( Figure 7D and 7E) , and chromatin immunoprecipitation assays confirmed a binding site of p65 in the Runx2 promoter ( Figure 7F ).
Taking these results together, we propose that MR409 blocks osteogenesis of SMCs and VC in vivo by activating GHRH-R on the surface of SMCs, leading to increased cAMP production and PKA activity. Activated PKA inhibits NADPH oxidase by dephosphorylation of p65, thereby reducing ROS production and blocking the RANK-mediated phosphorylation of NFκB and expression of IL-6, thereby blocking the osteogenic differentiation pathway (Figure 8 ). We propose that these effects are independent of GH or its biological effects. In support of the latter, we found no changes in the circulating levels Figure 3 . In vitro anticalcification effect of MR409 on mouse smooth muscle cells (mSMCs). mSMCs were cultured under osteogenic medium (OM) with or without MR409 for 2 to 3 wk. A, Calcific nodules were visualized by Alizarin Red (top) and Von Kossa (bottom) staining; (B) Alizarin Red in A was quantified by measuring optical density (OD) of the cell extraction (P<0.01); (C) total calcium; and (D) alkaline phosphatase (ALP) activity was measured (both P<0.001). E and F, Western blot analysis of Runx2, osteopontin, osteonectin, and osteocalcin. MR409 significantly blocked the increase of Runx2, osteonectin, and osteocalcin under OM (*P<0.01), and this effect can be attenuated by either the knock-down of growth hormone-releasing hormone receptor (GHRH-R) by specific small interfering RNA (siRNA) or the addition of GHRH antagonist, MIA602. However, osteopontin was not influenced by MR409. All data were collected from 3 independent experiments. *Compared with OM+MR409 group. MIA602 indicates antagonist of GHRH; MR409, agonist of GHRH; and OM, osteogenic medium.
of either GH or parathyroid hormones in mice treated acutely or for 4 weeks with MR409 (Online Figure XI) . In addition, 4 weeks of treatment of mice with MR409 had no effect on serum levels of IL-6, IL-10 (interleukin-10), MCP-1 (monocyte chemoattractant protein-1), calcium, or phosphate, and treated mice showed no differences in body weight or bone density relative to untreated (saline) groups (Online Figure Ⅺ) .
Discussion
Our work demonstrates that treatment of OPG −/− mice with GHRH agonist MR409 for 4 weeks significantly blocked VC (80% reduction of calcium volume) without affecting the serum levels of GH or any of the associated biological effects of elevated GH. The results imply that the activation of GHRH-R by MR409 can regulate diverse biological activities independently of its effects on GH-regulated pathways. This is consistent with previously reported GH-independent actions of GHRH-A on other vascular and cardiovascular functions. 19, 40, 47 We found that aortas of OPG −/− mice displayed increased levels of phosphorylated NFκB (p65) and Runx2, which are markers of osteogenic differentiation. Both of these were significantly reduced in the MR409 treatment groups. SMCs isolated from aortas of OPG −/− mice also displayed increased levels of phosphorylated NFκB (p65) and Runx2, as well as increased ROS and NADPH oxidase activities, all independent markers of enhanced osteogenesis. In all cases, the enhanced activities were blocked by treatment with MR409. Similar effects were observed when SMCs from human or mouse aortas were forced into osteogenic differentiation by culture in OM. In all cases, the enhanced activities of the osteogenic markers were blocked by MR409 treatment in parallel with reduced calcification. In addition, the inhibitory effects of MR409 on osteogenesis, including the blockade of each marker, as well as net resultant calcification, were reversed in the presence of PKA inhibitors, including a PKA-specific siRNA and selective chemical inhibitor H89. This is consistent with a central role for PKA in mediating cross talk between MR409-activated GHRH-R and the osteogenic cascade. The effects of MR409 were also antagonized by GHRH-antagonist MIA602 and GHRH-R-specific siRNA, confirming the specificity of the effects of MR409 on the GHRH-R pathway.
VC is a complex process known to include active and passive pathways. 48, 49 During the passive process, calcium binds to collagen and elastin fibrils on the surface of the vessel walls causing neutralization of charge of the fibrils and attraction of negatively charged phosphate and carbonate ions. This results in hydroxyapatite crystal nucleation and extracellular matrix calcification surrounding the vessel. Passive VC accumulates with age, driven by circulating levels of calcium and phosphate and can be inhibited by physiological levels of pyrophosphate. 50 It has been suggested that passive calcification accounts for as much as 85% of global VC. 28 Active or cellular calcification is a highly regulated process with parallels bone mineralization and morphogenesis. 7, 48 Ectopic calcification by active mineralization involves osteogenesis of cells in the vessel wall or plaques, including vascular SMCs and pericytes . Protein kinase A (PKA) mediated deactivation of NADPH oxidase and reactive oxygen species (ROS) production. A, Cytosolic cAMP in mouse smooth muscle cells (SMCs) at specified culture conditions. cAMP was significantly elevated after MR409 treatment, and the effect was partially abolished by addition of MIA602 (*P<0.01; n=3); (B) measurement of NADPH oxidase activity in mouse smooth muscle cells (mSMCs). The enhanced activity of NADPH oxidase under osteogenic medium (OM) condition was abolished by MR409 (*P<0.001; n=3). Inhibition of PKA by small interfering RNA (siRNA) or inhibitor H89 blocked the effect of MR409 ( §/&P<0.01; n=3); (C) quantification of ROS; and (D) Quantification of total calcium in mSMCs at specified culture conditions (*P<0.01; §/&P<0.001; n=3). E, Detection of calcification in mSMCs by Alizarin Red (AR) and Von Kossa (VK) staining. MR409 reduced calcium deposition under OM conditions, which was blocked by PKA inhibition. F, Measurement of NADPH oxidase activity in human smooth muscle cells (hSMCs). Inhibition of PKA by H89 in human SMCs also abolishes the MR409-mediated effect of NADPH oxidase deactivation (*P<0.0001; &P<0.001; n=3). G, Measurement of ROS in hSMCs. Blockage of ROS production by MR409 was attenuated when PKA was inhibited by H89 (*P<0.01; &P<0.05; n=3). All data were from 3 independent experiments. *, §, & were compared with the OM+MR409 group. ) mouse aorta. MR409 decreased the phosphorylation of p65, and the expression of IL-6 in the absence of OM and these effects were PKA dependent. G, Quantification of p-p65 and IL-6 expression in F (*P<0.01; n=3). All data were from 3 independent experiments. *Compared with the other groups.
or pericyte-like cells in the intimal and median layers of the arterial vasa vasorum. 29 The molecular and cellular pathways and regulation of active calcification are complex. Recognized molecular regulators include bone morphogenic proteins and the antagonist, matrix γ-carboxyglutamic acid protein. 51 Upstream physiological regulators of active VC include endothelial shear stress, inflammation, and elevated ROS that target the key osteoblastic master genes Msx2 and Runx2. 52 One such pathway involves the RANKL cytokine and its cell surface receptor RANK. Activation of RANK results in stimulation of NFκB (p65) signaling, induction of Msx-2 and Runx2, calcium resorption, and osteogenesis. Because this pathway is linked to oxidative stress and inflammation, it may be more closely associated with micro-or speckled calcification and the generation of unstable atherosclerotic lesions. 2, 8, 28, 29, 53, 54 Speckled calcification, while not detected by standard calcium screening techniques, is detected by more sensitive techniques, for example, by scanning of 18F-sodium fluoride uptake into hydroxyapatite (positron emission tomography). 55 Using this technique, it has been shown that speckled calcification is frequently associated with ruptured plaque after acute myocardial infarction and may in fact predispose plaques to rupture. 4, 55 Osteoprotegerin is a naturally occurring cytokine of the tumor necrosis factor receptor superfamily, which is secreted by endothelial cells, SMCs, and osteoblasts and inhibits activation of RANK, thereby antagonizing inflammation-induced osteogenesis and VC. 56 Osteoprotegerin deficiency may be an appropriate model to study mechanisms of the inflammation-driven microcalcification process because it mimics the pathological pathway that is rapid and involves limited input from passive calcification. 57, 58 Especially at early time points, OPG −/− mice may indeed be an ideal mouse model for studying low density or speckled plaque and unstable plaque formation. 2, 8, 28, 29, 53, 54 MR409 is a synthetic peptide of 29 amino acids that contains the active site of GHRH and adjacent peptide modifications that enhance activity and stability. 23 It was shown that administration of MR409 at the doses used here did not affect GH serum levels in pigs or rats. 40, 59 We similarly found that MR409 did not elevate serum GH in mice (Online Figure  ⅪB) . Physiological studies on mice showed an absence of any GH-related effects caused by MR409 administration (see Online Figure Ⅺ) . GHRH-Rs have been described on multiple cell types, in addition to pituitary cells. 19, 42 We previously reported that GHRH agonist JI-34 significantly enhanced the viability, mobility, and proangiogenic properties of mesenchymal stem cells. 19 The present study reveals the existence of GHRH receptors on SMCs (Online Figure Ⅳ) .
Oxidative stress and endoplasmic reticulum stress are both implicated in VC and have been shown to promote osteogenetic differentiation of SMCs. 30 We found that the level of ROS in both mouse and human SMCs was significantly increased under OM conditions, and this elevation was blocked by MR409 (Figure 4A and 4B; Online Figure ⅣA and IVB) . ROS levels were accompanied by parallel changes in activity of NADPH oxidase. Previous reports have shown that the binding of MR409 to GHRH-R may cause activation of several signaling pathways, including cAMP/PKA, 41, 60 PI3K (phosphoinositide 3-kinase)/Akt, 24, 41 and ERK. 24 We found that phosphorylation of Akt was significantly increased in SMCs cultured under OM conditions, consistent with previous reports that phosphorylated Akt promotes calcification of SMC. 30, 31 Interestingly, however, the addition of MR409 to the osteogenic cultures did not change Akt phosphorylation levels (Online Figure XII) .
The regulation of the release of GH from the pituitary by GHRH is mediated through mechanisms involving the cAMP/ PKA signaling pathway. 60 Consistent with this, we found that cAMP levels in SMCs were significantly increased by MR409. This effect was blocked by GHRH antagonist MIA602 ( Figure 5A ), confirming selectivity of the effect on the GHRH-A receptor pathway. Furthermore, inhibition of PKA by specific siRNA or chemical inhibitor H89 resulted in higher activity of NADPH oxidases, increased ROS production ( Figure 5B and 5C), and calcification ( Figure 5D and 5E). These results suggest that the inhibitory function of MR409 is mediated through the cAMP/PKA pathway. Previous studies have shown that phosphorylation of Ser 172 and Ser 461 residues of Nox1 by PKA causes inactivation of NAPDH oxidase-1 33 , consistent with such a mechanism for MR409. It is interesting to note that adrenomedullin treatment also activates cAMP/PKA signaling, and this is accompanied by increased expression of osteopontin and attenuated VC. 38 Conversely, Tintut et al 61 reported that the elevation of cAMP markedly promoted calcification of vascular Figure 8 . Schematic diagram of the anticalcification effect of agonists of growth hormone-releasing hormone (GHRH-A). The binding of GHRH-A (MR409) to GHRH receptor activates the cAMP/protein kinase A (PKA) signaling pathway, resulting in inhibition of NADPH oxidase activity and dephosphorylation of nuclear factor κB (p65), which leads to the reduction of reactive oxygen species (ROS) and IL-6 (interleukin-6). Such effects of GHRH-A can be blocked by GHRH antagonist, MIA602, by small interfering RNA (siRNA) of GHRH receptor and PKA, and by chemical inhibitor H89. Reduction of ROS attenuates the expression of osteogenic genes, such as transcription factor Runx2, osteonectin, osteocalcin, and alkaline phosphatase. Finally, these changes lead to the inhibition of calcium phosphate deposition.
cells. These apparent discrepancies could be because of different cell types and experimental details.
NFκB (p65) plays a pivotal role in VC. 62 In our studies, osteoprotegerin deficiency resulted in an elevation of serum RNAKL ( Figure 7A ) and sustained activation of the NFκB (p65) signaling pathway. We found that phosphorylation of NFκB (p65) in aortas of OPG −/− mice was higher than that in wild-type mice, and administration of MR409 to OPG −/− mice significantly decreased the phosphorylation of p65 ( Figure 7B  and 7C) . Similarly, SMCs derived from OPG −/− aortas showed a high ratio of p-p65 to p65 that was blocked by MR409. Inhibition of PKA by siRNA or H89 significantly reduced the effects of MR409, confirming that PKA inhibits p65 phosphorylation. Furthermore, we found that OM conferred elevation of the p-p65 to p65 ratio in SMCs ( Figure 6A and 6B) . This was also blocked in a PKA-dependent manner by MR409 ( Figure 6A and 6B) . These data confirm that activation of PKA by MR409 promotes dephosphorylation of NFκB (p65).
Although our results are consistent with most other reports on the roles of PKA-NFκB signaling, 35, 63 the relationships are controversial. Ollivier et al 35 found that in human monocytes and endothelial cells, NFκB-mediated transcription was significantly inhibited by elevated cAMP or by overexpression of the catalytic subunit of PKA. Zuo et al 63 also found that activation of PKA negatively regulated the expression of NFκB in the sympathetic nervous system. This is at variance with Zhong et al 64 who found that PKA promoted the phosphorylation of p65 on serine 276 , thereby modulating its interaction with CBP/p300. The discrepancies may be because of high cell type specificity of the signaling pathways involved, as well as hierarchies and priorities of the pathways, cross talk, and experimental conditions.
Because the anticalcification effects of our GHRH-A treatments seem to operate entirely independently of GH signaling, they suggest novel and potentially safe approaches to reduce the calcification that has been causally linked with multiple indications of cardiovascular disease. These include but are not necessarily limited to aorta media calcification, 65 heart valve calcification, 66 and calcification-related vessel stiffness in kidney disease. 67 Insufficient scavenging of ROS 27, 32 and the associated increased activity of NADPH oxidases 68, 69 contribute to the enhanced calcification and adverse pathologies in each of these instances. RANK activation is also a driving force that exacerbates medial arterial calcification and in some cases may confer plaque instability by increasing microcalcification. 36, 70 Our results show that systemic treatment with the GHRH-A MR409 activates cAMP/PKA signaling in SMCs, and this in turn inhibits NADPH oxidase activity, reduces ROS, and inhibits RANK/ NFκB signaling, thereby blocking calcification without apparent side effects. Therefore, we propose that MR409 or related GHRH-A may provide a novel and safe approach to block pathological VC even with chronic administration (Online Figure Ⅺ) .
In conclusion, activation of GHRH receptors on SMCs by GHRH-A MR409 significantly impeded calcification in both in vitro and in vivo models of VC. Evidence is provided to support a cross talk between RANKL-NFκB-Runx2 and GHRHR-cAMP-PKA and NADPH oxidase signaling pathways as the mechanisms for the suppression of active cellular osteogenesis and VC by MR409 (Figure 8 ). We further propose that MR409 may be a safe approach to inhibit speckled calcification on atherosclerotic plaque and maintain plaque stability in vulnerable patients. Further studies are needed to directly examine the effects of MR409 treatments specifically on speckled calcification and plaque stability.
